JAMA Editors' Summary From ESC: Remote Monitoring for Atrial Fibrillation, Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction, RSV Vaccine to Prevent Hospitalizations in Older Adults, and more
14 snips
Sep 1, 2025 Gregory Curfman, Executive Editor at JAMA, and Robert O. Bonow, JAMA Cardiology Editor, tackle pressing advancements in cardiac care. They discuss the benefits of remote ECG monitoring for atrial fibrillation detection and the safety of discontinuing anticoagulants post-ablation. The duo also dives into the comparative effectiveness of semaglutide and tirzepatide in heart failure treatment. Lastly, they underscore the significance of bivalent RSV vaccination for older adults, while highlighting the need for greater female representation in cardiovascular trials.
AI Snips
Chapters
Transcript
Episode notes
H. pylori Screening After MI Was Not Protective
- Routine H. pylori screening after MI did not reduce postdischarge upper GI bleeding in this large pragmatic trial.
- The null result suggests screening may not change GI bleeding outcomes in unselected MI populations.
Complete Revascularization Helps Older MI Patients
- In patients >75 with MI and multivessel disease, complete revascularization reduced the 3‑year composite of death, MI, stroke, or revascularization.
- Benefits persisted beyond year one and notably reduced heart-failure hospitalizations.
Complete Revascularization Benefits NSTEMI Mostly By Fewer Repeats
- For non–ST-elevation MI, complete revascularization reduced a one-year composite outcome versus culprit-only PCI.
- The primary benefit was driven mainly by fewer repeat revascularizations.